Log In
Print
BCIQ
Print
Print this Print this
 

HuMax-CD38, daratumumab

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman mAb against CD38
Molecular Target CD38
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,715.9M

$70.0M

$1,566.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today